This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record.
1. Trial at a Glance
ICON7 was a randomized phase 3 treatment trial evaluating carboplatin and paclitaxel with or without bevacizumab in patients with newly diagnosed ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cavity cancer. The registry identifies progression-free survival as the primary endpoint.
| Feature | ICON7 |
|---|---|
| Trial acronym | ICON7 |
| NCT identifier | NCT00483782 |
| Phase | Phase 3 |
| Status | Completed |
| Start date | 2006-04 |
| Lead sponsor | Medical Research Council |
| Sponsor type | Other government |
| Allocation | Randomized |
| Masking | None |
| Primary purpose | Treatment |
| Enrollment | 1,520 |
| Primary endpoint | Progression-free survival |
2. Clinical Question
The clinical question is whether adding bevacizumab to carboplatin and paclitaxel changes progression-free survival in patients with newly diagnosed ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cavity cancer.
Population
Patients with newly diagnosed ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cavity cancer.
Intervention
Carboplatin and paclitaxel with bevacizumab.
Comparator
Carboplatin and paclitaxel without bevacizumab.
Primary question
Does treatment with carboplatin and paclitaxel plus bevacizumab affect progression-free survival compared with carboplatin and paclitaxel without bevacizumab?
3. Trial Design
The registry describes ICON7 as a randomized, unmasked, phase 3 treatment trial. The enrollment target represented a large randomized population of 1,520 patients.
Carboplatin + paclitaxel + bevacizumab
- Bevacizumab
- Carboplatin
- Paclitaxel
Carboplatin + paclitaxel
- Carboplatin
- Paclitaxel
- No bevacizumab
4. Population and Disease Setting
The registry identifies three conditions within the ICON7 study population:
| Condition | Registry status |
|---|---|
| Ovarian Cancer | Condition under study |
| Fallopian Tube Cancer | Condition under study |
| Primary Peritoneal Cavity Cancer | Condition under study |
The title specifies that the cancers are newly diagnosed. The registry therefore frames ICON7 as an intervention trial in an initial treatment setting rather than a study limited to a later line of therapy.
5. Interventions
The registry lists six intervention components or study activities. The treatment comparison is centered on bevacizumab in combination with carboplatin and paclitaxel, while several additional activities relate to study assessment and data collection.
| Registry intervention | Type | Statistical relevance |
|---|---|---|
| Bevacizumab | Biological | Defines the principal treatment contrast |
| Carboplatin | Drug | Component of the chemotherapy regimen |
| Paclitaxel | Drug | Component of the chemotherapy regimen |
| Questionnaire administration | Other | Study assessment activity |
| Study of socioeconomic and demographic variables | Other | Study data-collection activity |
| Quality-of-life assessment | Procedure | Patient-reported or quality-of-life assessment activity |
6. Primary Endpoint
| Endpoint | Registry information | Statistical perspective |
|---|---|---|
| Progression-free survival | Listed as the primary endpoint | Typically analyzed as a time-to-event endpoint |
The registry record identifies progression-free survival as the primary endpoint. The registry information available here does not provide a further endpoint definition or a specific assessment time frame.
7. Planned Analysis
No formal statistical analyses are posted in the ClinicalTrials.gov record. The appropriate statistical framework for the registered primary endpoint can nevertheless be described from the nature of the endpoint.
Progression-free survival as a time-to-event outcome
Progression-free survival records the time until a prespecified event. Unlike a simple binary endpoint, patients can have different lengths of follow-up, and some patients may not experience the event during observation. This makes time-to-event methods appropriate for the primary analysis.
Here, T represents the time to the event of interest. The survival function describes the probability that the event has not occurred by time t.
Kaplan-Meier estimation
A Kaplan-Meier estimator would ordinarily be used to describe the distribution of progression-free survival over time. It can incorporate right-censored observations, allowing patients who have not experienced the endpoint by their last observed assessment to contribute information up to that point.
At each observed event time, di is the number of events and ni is the number of patients at risk immediately before that time.
Comparing the randomized groups
For a randomized two-group trial with progression-free survival as the primary endpoint, a log-rank test is a standard method for comparing time-to-event distributions. A Cox proportional-hazards model is commonly used to estimate a hazard ratio and its confidence interval.
Hazard ratio framework
A hazard ratio below 1 would correspond to a lower estimated instantaneous event rate in the bevacizumab-containing group under the fitted model.
This is a statistical interpretation of an effect estimate, not a statement about the actual outcome of ICON7.
Why the analysis requires more than a p-value
A time-to-event comparison is best understood through several complementary quantities: the estimated survival curves, the relative effect estimate, its confidence interval, and clinically interpretable absolute measures at relevant time points. A p-value addresses evidence against a specified null hypothesis; it does not quantify the magnitude or practical importance of an effect.
8. Statistical Methodology
Randomization
Randomization is the central design feature that allows the treatment groups to be compared as assigned rather than relying on observational adjustment alone. In a randomized trial, treatment assignment is determined before the outcome is observed, helping balance both measured and unmeasured prognostic factors in expectation.
Time-to-event analysis
Progression-free survival differs from a fixed-time binary endpoint because both whether an event occurs and when it occurs are relevant. Time-to-event methods preserve information from patients who have different observation times and from patients whose event status remains unresolved at the end of follow-up.
Right censoring
Patients can be censored when their progression-free survival time cannot be observed completely during the study observation period. Proper censoring rules are essential because treating censored patients as though they experienced the event, or as though they were event-free indefinitely, would distort the estimated survival distribution.
Cox proportional-hazards model
A Cox model expresses the hazard for an individual as a baseline hazard multiplied by a relative-risk component. In a simple two-group comparison, the treatment coefficient can be exponentiated to obtain a hazard ratio.
For a binary treatment indicator, exp(β) represents the estimated hazard ratio comparing the two treatment groups under the proportional-hazards model.
Proportional-hazards assumption
The conventional Cox hazard ratio has its clearest interpretation when the relative hazard is reasonably stable over time. If treatment effects vary substantially during follow-up, a single hazard ratio can compress a changing treatment effect into one summary number. Alternative summaries, such as restricted mean survival time or fixed-time survival probabilities, can sometimes provide additional insight.
9. Statistical Methods Explained
Why is progression-free survival analyzed as a time-to-event endpoint?
Because patients can experience progression at different times and may have different amounts of follow-up. A time-to-event analysis uses both dimensions rather than reducing every patient to a simple yes/no status at one arbitrary date.
Why would a Kaplan-Meier curve be useful?
A Kaplan-Meier curve provides a visual description of the proportion of patients who remain event-free over time. It also makes the timing of events and the presence of censoring visible in a way that a single summary statistic cannot.
What would a hazard ratio mean in ICON7?
If a hazard ratio were estimated for progression-free survival, it would compare the instantaneous event rates between the bevacizumab-containing and comparator groups under the fitted model. A value below 1 would indicate a lower estimated event hazard in the bevacizumab group.
Why is a confidence interval important?
A point estimate alone does not show how precisely the treatment effect has been estimated. A confidence interval provides a range of effect estimates compatible with the statistical model and observed information under the chosen confidence level.
Why does randomization matter statistically?
Randomization establishes the treatment assignment mechanism before outcomes are observed. This reduces systematic differences in expected prognostic factors between treatment groups and supports a causal interpretation of a well-conducted randomized comparison.
What does an unmasked design change?
When treatment assignment is not masked, knowledge of treatment can potentially influence behavior, assessment, reporting, management after treatment, or other aspects of trial conduct. The importance of this issue depends on how the endpoint is defined and assessed.
10. Analysis Populations and Interpretation
The registry information identifies randomized allocation but does not provide specific analysis-population definitions. In a randomized phase 3 trial, the analysis population is an important component of the statistical interpretation because different populations answer different questions.
| Population concept | Statistical purpose |
|---|---|
| Intention-to-treat | Preserves the randomized comparison by analyzing patients according to their assigned treatment group. |
| Per-protocol | Focuses on patients who sufficiently adhered to protocol-defined treatment and assessment requirements. |
| Safety population | Typically focuses on patients who actually received study treatment and therefore had treatment exposure. |
These populations should not be treated as interchangeable. The ITT principle is particularly important for preserving the benefits of randomization when estimating the effect of treatment assignment.
11. Missing Data and Censoring
The ClinicalTrials.gov record does not specify the trial's detailed missing-data or censoring rules. For progression-free survival, these rules are statistically important because incomplete follow-up is not equivalent to a confirmed progression event.
Censoring
A censored observation contributes information up to the time at which the patient can no longer be followed for the endpoint under the specified analysis rules.
Missing assessments
Missing disease assessments can affect the determination of progression and therefore can influence both event classification and censoring.
Why rules matter
Different censoring conventions can produce different estimates even when the underlying patient data are identical.
Interpretation
The statistical analysis should therefore follow prespecified definitions rather than allowing outcome classification to depend on post hoc choices.
12. Multiplicity
The registry identifies progression-free survival as the primary endpoint and does not list additional registered primary endpoints in the record described here.
Multiplicity becomes important when investigators formally test multiple hypotheses, endpoints, treatment contrasts, time points, or subgroup interactions. When several statistical tests are performed, the probability of obtaining at least one apparently positive result can exceed the nominal significance level unless the testing strategy accounts for the multiplicity.
13. Interim Analysis
The ClinicalTrials.gov record does not report an interim-analysis schedule, interim efficacy boundary, alpha-spending method, or stopping rule.
In general, an interim analysis examines accumulating trial information before the planned final analysis. If the same hypothesis is tested repeatedly without an appropriate group-sequential adjustment, the overall type I error can be inflated. Prespecified interim boundaries or alpha-spending procedures are therefore used when interim efficacy or futility monitoring is part of the design.
14. Non-Inferiority, Factorial, and Bayesian Methods
| Design topic | Registry information | Statistical interpretation |
|---|---|---|
| Non-inferiority | Not identified | No non-inferiority margin is reported in the ClinicalTrials.gov record. |
| Factorial design | Not identified | The registry describes a randomized treatment comparison rather than reporting a factorial design. |
| Bayesian methods | Not identified | No Bayesian analysis is reported in the ClinicalTrials.gov record. |
| Interim analysis | Not reported | No interim-analysis method or stopping boundary is reported. |
These distinctions matter because the inferential framework depends on the question being tested. A non-inferiority trial, for example, requires a prespecified margin and a different interpretation from a conventional superiority comparison. A Bayesian analysis would likewise require explicit prior and posterior specifications.
15. Quality-of-Life and Other Study Assessments
The registry lists quality-of-life assessment, questionnaire administration, and the study of socioeconomic and demographic variables among the trial interventions or study activities.
| Study activity | Registry classification |
|---|---|
| Questionnaire administration | Other |
| Study of socioeconomic and demographic variables | Other |
| Quality-of-life assessment | Procedure |
These activities broaden the data collected during the trial beyond the primary progression-free survival endpoint. However, the registry information available here does not provide their numerical results or formal statistical analysis.
16. Safety
The registry lists bevacizumab, carboplatin, and paclitaxel as treatment interventions but does not provide serious adverse-event counts by treatment arm in the information available here.
Consequently, the safety interpretation is limited to the trial's design context. A randomized treatment comparison involving a biological agent and chemotherapy would ordinarily require adverse events to be summarized separately by treatment group, including serious adverse events and other prespecified safety categories.
17. What a Complete PFS Analysis Would Contain
A statistically complete analysis of the registered primary endpoint would normally combine several complementary elements rather than relying on one test statistic.
| Component | Purpose |
|---|---|
| Kaplan-Meier estimates | Describe progression-free survival over follow-up. |
| Median PFS | Summarize the time at which the estimated survival probability reaches 0.50, when estimable. |
| Hazard ratio | Summarize the relative event hazard between treatment groups under a fitted survival model. |
| Confidence interval | Quantify statistical uncertainty around the effect estimate. |
| Log-rank test | Provide a hypothesis test comparing time-to-event distributions. |
| Number of events | Indicate the amount of observed endpoint information contributing to the analysis. |
| Censoring description | Show how incomplete follow-up and unresolved progression were handled. |
The registry record identifies the endpoint but does not provide these numerical analysis results. The appropriate interpretation of the trial therefore depends on the distinction between a registered endpoint and a posted statistical result.
18. Limitations
- No posted statistical analyses: the ClinicalTrials.gov record does not contain posted statistical analyses for the registered primary endpoint.
- Limited endpoint detail: the registry information identifies progression-free survival but does not provide its detailed operational definition or time frame.
- No numerical efficacy results: the registry information available here does not report an estimate, confidence interval, p-value, event count, or median for progression-free survival.
- No arm-specific sample sizes: the total enrollment is 1,520, but the ClinicalTrials.gov record does not state the number assigned to each treatment group.
- No baseline table: baseline demographic and clinical characteristics are not reported in the registry information available here.
- No safety counts by arm: serious adverse-event counts and other numerical safety outcomes are not reported in the information available here.
- No subgroup results: subgroup-specific treatment effects are not reported in the registry information available here.
- No interim-analysis details: the registry information does not describe interim looks, efficacy boundaries, or alpha spending.
- No detailed missing-data strategy: the registry information does not specify how missing assessments or censoring were handled for the primary endpoint.
- Unmasked design: treatment assignment was not masked, which can matter for endpoints susceptible to knowledge of treatment assignment.
19. Why This Trial Matters Statistically
ICON7 provides a useful framework for understanding how a large randomized oncology trial is structured around a time-to-event primary endpoint. The registry combines a randomized phase 3 treatment comparison with a clearly identified primary endpoint of progression-free survival.
| Concept | How it appears in ICON7 |
|---|---|
| Randomization | The allocation is explicitly described as randomized. |
| Phase 3 design | The trial is identified as phase 3. |
| Time-to-event endpoint | Progression-free survival is the registered primary endpoint. |
| Comparative treatment evaluation | Carboplatin and paclitaxel are evaluated with or without bevacizumab. |
| Unmasked treatment | The registry identifies masking as none. |
| Large enrollment | The study enrolled 1,520 patients. |
| Endpoint interpretation | PFS requires attention to event timing, censoring, and follow-up. |
| Quality-of-life assessment | Quality-of-life assessment is listed among the study activities. |
| Additional data collection | Questionnaires and socioeconomic/demographic variables are also listed. |
20. Statistical Interpretation of a Future Hazard Ratio
If a future analysis of ICON7 reported a progression-free survival hazard ratio below 1 for bevacizumab plus chemotherapy versus chemotherapy alone, the estimate would indicate a lower modeled instantaneous rate of progression or another prespecified PFS event in the bevacizumab group.
It would not mean that the same percentage of every patient experienced a reduction in risk, nor would it directly provide the absolute difference in progression-free survival at a particular time point.
A confidence interval would show the statistical precision of the estimated hazard ratio. A narrow interval would indicate greater precision than a wide interval, all else being equal. The interval would not describe the range of treatment effects experienced by individual patients.
A p-value evaluates compatibility with a specified null hypothesis under the statistical model. It does not tell the reader how large the treatment effect is. Effect size, confidence interval, and absolute outcome measures are needed to understand magnitude and precision.
21. Statistical Analysis Questions Raised by ICON7
What exactly counts as progression?
The operational definition determines which observations become PFS events and which remain event-free or censored. The detailed registry information available here does not provide that definition.
How should censoring be handled?
Censoring rules determine how patients without an observed endpoint event contribute information to the survival analysis.
Should treatment effects be adjusted for baseline factors?
The answer depends on the prespecified statistical analysis plan and randomization structure. Adjustment can improve precision, but post hoc selection of covariates can complicate inference.
Does an unmasked design invalidate PFS?
No. Randomization remains a central design feature, but knowledge of treatment assignment can matter if assessment or clinical management can influence the endpoint.
Why report both relative and absolute effects?
A hazard ratio summarizes relative event rates, while survival probabilities or other fixed-time measures provide an absolute view of outcomes. They answer different statistical questions.
Why does sample size matter?
A total enrollment of 1,520 provides a substantial randomized population, but statistical precision depends on the number and timing of observed primary endpoint events as well as follow-up and censoring.
22. Registry Timeline
Trial starts
The registry lists April 2006 as the study start date.
Randomized treatment comparison
The study is identified as a randomized phase 3 treatment trial comparing carboplatin and paclitaxel with or without bevacizumab.
Large randomized study population
The registry reports enrollment of 1,520 patients across the study.
Study status
The ClinicalTrials.gov record identifies the trial status as completed.
23. Clinical Interpretation vs Statistical Interpretation
Statistical interpretation
ICON7 is a randomized phase 3 trial with progression-free survival as its registered primary endpoint. A conventional analysis would treat PFS as a time-to-event outcome and would emphasize survival estimates, treatment-effect estimates, uncertainty, and prespecified testing.
Clinical interpretation
The clinical question concerns whether adding bevacizumab to carboplatin and paclitaxel changes progression-free survival in newly diagnosed ovarian epithelial, fallopian tube, or primary peritoneal cavity cancer.
24. What the Registry Establishes
The registry establishes several important design facts without supplying the numerical efficacy analysis needed to quantify the treatment effect.
| Question | Registry information |
|---|---|
| What was studied? | Carboplatin and paclitaxel with or without bevacizumab. |
| Who was studied? | Patients with newly diagnosed ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cavity cancer. |
| What was the trial phase? | Phase 3. |
| How was treatment assigned? | Randomized. |
| Was treatment masked? | No; masking is listed as none. |
| How many patients enrolled? | 1,520. |
| What was the primary endpoint? | Progression-free survival. |
| Was a formal statistical analysis posted? | No. |
25. Sources
- ClinicalTrials.gov: ICON7 — NCT00483782.
- PubMed: PubMed record associated with ICON7.
- PubMed: PubMed record associated with ICON7.
- PubMed: PubMed record associated with ICON7.
Continue through the Clinical Biostats knowledge graph
Explore clinical trial methodology, survival analysis, and statistical interpretation across the Clinical Biostats library.
26. Record Summary
ICON7 is a randomized phase 3 treatment trial that enrolled 1,520 patients and evaluated carboplatin and paclitaxel with or without bevacizumab in newly diagnosed ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cavity cancer. The registry identifies progression-free survival as the primary endpoint and identifies the study as unmasked.
From a statistical perspective, the central analytical problem is a randomized comparison of a time-to-event endpoint. A rigorous PFS analysis would ordinarily combine Kaplan-Meier estimation, appropriate handling of censoring, a treatment-effect measure such as a hazard ratio with its confidence interval, and a prespecified hypothesis test. The interpretation should then consider the analysis population, endpoint definition, follow-up, missing assessments, and assumptions underlying the chosen model.